OncoCyte Corporation (OCX)

3,0700 +0,1800 (+6,23%) Al cierre: 04:00PM EDT

OncoCyte Corporation

15 Cushing
Irvine, CA 92618
United States
949 409 7600
https://www.oncocyte.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 43

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Joshua Riggs	President, CEO & Director	504,63k	N/A	1983
Mr. James Liu	Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer	259,83k	N/A	1996
Dr. Ekkehard Schutz M.D., Ph.D.	Chief Science Officer	409,27k	N/A	N/A
Mr. Peter Hong	VP, General Counsel & Secretary	N/A	N/A	N/A
Mr. Yuh-Min Chiang Ph.D.	Senior Vice President of R&D and Product Development	N/A	N/A	N/A
Ms. Sandra O'Donald	Senior Vice President of Business Operations	N/A	N/A	N/A
Dr. Michael D. West Ph.D.	Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.	N/A	N/A	1953

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Gobierno corporativo

El ISS Governance QualityScore de OncoCyte Corporation, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.